Satellos Bioscience Inc. (TSX:MSCL)

Canada flag Canada · Delayed Price · Currency is CAD
0.6500
+0.0100 (1.56%)
Apr 30, 2025, 3:59 PM EDT
44.44%
Market Cap 106.13M
Revenue (ttm) n/a
Net Income (ttm) -28.10M
Shares Out 165.82M
EPS (ttm) -0.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 109,521
Average Volume 135,577
Open 0.6600
Previous Close 0.6400
Day's Range 0.6500 - 0.6900
52-Week Range 0.3800 - 1.3200
Beta 0.70
RSI 46.32
Earnings Date May 14, 2025

About Satellos Bioscience

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British C... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 17
Stock Exchange Toronto Stock Exchange
Ticker Symbol MSCL
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.